MediciNova begins producing vector for its intranasal COVID-19 vaccine
MediciNova has begun good manufacturing practice-based master virus seed stock production of its novel intranasal SARS-CoV-2 vaccine for COVID-19.
Twist Bioscience touts positive preclinical data for SARS-CoV-2 antibodies
Twist Bioscience has touted preclinical results for three of its proprietary antibodies against the novel coronavirus S1 subunit protein.
Families weigh risks of coronavirus exposure over Thanksgiving
Parents are weighing the risks and benefits of gathering with extended family this year, amidst the global COVID-19 pandemic. Most parents are planning to prioritize continuing Thanksgiving traditions while reducing transmission risks, according to a new national Mott Poll.  Discuss
Ad Council launches $50M COVID-19 vaccine education effort
The Ad Council will launch a communications campaign to encourage vaccination against the novel coronavirus.
AstraZeneca COVID-19 vaccine achieves 70% efficacy
AstraZeneca released interim analysis from clinical trials of AZD1222, its COVID-19 vaccine candidate in the U.K. and Brazil, with data demonstrating it met the primary endpoint of preventing COVID-19.
FDA issues EUA for Regeneron's COVID-19 mAb cocktail
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) on November 21 for the casirivimab and imdevimab monoclonal antibody (mAb) cocktail. The mAb cocktail is for the treatment of mild to moderate symptoms in patients with COVID-19 who are at a high risk for progressing to severe COVID-19.
FDA to review Pfizer, BioNTech's vaccine EUA on December 10
The Vaccines and Related Biological Products Advisory Committee of the U.S. Food and Drug Administration (FDA) has set a date of December 10 to discuss the request for emergency use authorization (EUA) of Pfizer and BioNTech's COVID-19 vaccine candidate.
Novartis secures exclusive rights to potential COVID-19 cell therapy
Novartis has entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize, and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome, which can be seen in COVID-19 patients.
Dr. Anthony Fauci breaks down the importance of COVID-19 vaccines
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, discussed the perils and opportunities of public trust during the COVID-19 pandemic, especially pertaining to the development of vaccines. The conversation took place on November 19 and was part of the Hastings Center's series Securing Health in a Troubled Time.
FDA issues EUA for Lilly's JAK inhibitor plus remdesivir for COVID-19
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the drug baricitinib, a janus kinase (JAK) inhibitor, in combination with remdesivir for the treatment of COVID-19 in hospitalized patients.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter